​

ORIC Pharmaceuticals (ORIC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ORIC Stock Forecast

ORIC Pharmaceuticals (ORIC) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $22.00, with a high of $25.00 and a low of $18.00. This represents a 126.80% increase from the last price of $9.70.

$5 $9 $13 $17 $21 $25 High: $25 Avg: $22 Low: $18 Last Closed Price: $9.7

ORIC Stock Rating

ORIC Pharmaceuticals stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 10 Strong Sell Sell Hold Buy Strong Buy

ORIC Price Target Upside V Benchmarks

TypeNameUpside
StockORIC Pharmaceuticals126.80%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts224
Avg Price Target$24.00$24.00$19.50
Last Closing Price$9.70$9.70$9.70
Upside/Downside147.42%147.42%101.03%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 251121--14
Nov, 25210---12
Oct, 25210---12
Sep, 25210---12
Aug, 25210---12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 08, 2025Wells Fargo$25.00$11.00127.27%157.73%
Nov 14, 2025H.C. Wainwright$23.00$12.7879.97%137.11%
Sep 04, 2025Brad CaninoGuggenheim$18.00$10.6069.81%85.57%
May 06, 2025Matthew BieglerOppenheimer$12.00$5.04138.10%23.71%
Sep 05, 2024Bradley CaninoStifel Nicolaus$20.00$9.48110.97%106.19%
Mar 21, 2024Robert BurnsH.C. Wainwright$21.00$14.5943.93%116.49%
Mar 12, 2024David NierengartenWedbush$20.00$14.6336.71%106.19%
Mar 12, 2024Matthew BieglerOppenheimer$17.00$14.3218.72%75.26%
Apr 05, 2022Yigel NochomovitzCitigroup$7.00$6.901.45%-27.84%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 08, 2025Wells FargoOverweightOverweighthold
Nov 14, 2025H.C. WainwrightBuyBuyhold
May 06, 2025OppenheimerOutperformOutperformhold
Sep 19, 2024H.C. WainwrightBuyBuyhold
Jul 10, 2024OppenheimerOutperformOutperformhold
May 07, 2024CitigroupBuyBuyhold
Mar 21, 2024NeedhamBuyBuyhold
Mar 12, 2024OppenheimerOutperformOutperformhold
Mar 23, 2023H.C. WainwrightBuyupgrade
Mar 21, 2023GuggenheimBuyupgrade

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.96$-1.83----
Avg Forecast$-1.96$-1.86$-2.04$-2.12$-2.19$-1.58
High Forecast$-1.91$-1.84$-1.90$-1.47$-1.52$-1.58
Low Forecast$-2.02$-1.88$-2.20$-2.69$-3.04$-1.58
Surprise %--1.61%----

Revenue Forecast

$15M $29M $43M $57M $71M $85M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$15.70M$15.15M$81.00M
High Forecast---$15.70M$15.15M$81.00M
Low Forecast---$15.70M$15.15M$81.00M
Surprise %------

Net Income Forecast

$-160M $-143M $-126M $-109M $-92M $-75M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-100.70M$-127.85M----
Avg Forecast$-100.70M$-95.65M$-105.55M$-107.17M$-117.24M$-81.46M
High Forecast$-98.06M$-94.61M$-97.73M$-75.74M$-77.99M$-81.46M
Low Forecast$-103.74M$-96.69M$-113.37M$-138.61M$-156.49M$-81.46M
Surprise %-33.66%----

ORIC Forecast FAQ

Is ORIC Pharmaceuticals stock a buy?

ORIC Pharmaceuticals stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ORIC Pharmaceuticals is a favorable investment for most analysts.

What is ORIC Pharmaceuticals's price target?

ORIC Pharmaceuticals's price target, set by 10 Wall Street analysts, averages $22 over the next 12 months. The price target range spans from $18 at the low end to $25 at the high end, suggesting a potential 126.80% change from the previous closing price of $9.7.

How does ORIC Pharmaceuticals stock forecast compare to its benchmarks?

ORIC Pharmaceuticals's stock forecast shows a 126.80% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for ORIC Pharmaceuticals over the past three months?

  • December 2025: 7.14% Strong Buy, 85.71% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is ORIC Pharmaceuticals’s EPS forecast?

ORIC Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.04, marking a 11.48% increase from the reported $-1.83 in 2024. Estimates for the following years are $-2.12 in 2026, $-2.19 in 2027, and $-1.58 in 2028.

What is ORIC Pharmaceuticals’s revenue forecast?

ORIC Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $15.7M, followed by $15.15M for 2027, and $81M for 2028.

What is ORIC Pharmaceuticals’s net income forecast?

ORIC Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-106M, representing a -17.44% decrease from the reported $-128M in 2024. Projections indicate $-107M in 2026, $-117M in 2027, and $-81.464M in 2028.